Table 1.
Baseline demographic and clinical characteristics of subjects who maintained the eradicated state by quadruple therapy (EBMT) or moxifloxacin-based triple therapy (MEA)
|
Variable category |
Total |
EBMT |
MEA |
p-value* |
|---|---|---|---|---|
| (N = 175) | (N = 59) | (N = 116) | ||
|
Gender |
(N = 175) |
(n = 59) |
(n = 116) |
|
| Male |
(104, 59.4%) |
(35, 59.3%) |
(69, 59.5%) |
0.98 |
| Female |
(71, 40.6%) |
(24, 40.7%) |
(47, 40.5%) |
|
|
Age (years) (mean ± SD) |
(N = 175) |
(n = 59) |
(n = 116) |
0.67 |
| (56.6 ± 9.4) |
(56.1 ± 9.3) |
(56.8 ± 9.5) |
||
|
Clinical diagnosis |
(N = 175) |
(n = 59) |
(n = 116) |
|
| Early gastric cancer |
(40, 22.9%) |
(11, 18.6%) |
(29, 25.0%) |
0.06 |
| Dysplasia |
(19, 10.9%) |
(3, 5.1%) |
(16, 13.8%) |
|
| Peptic ulcer disease |
(34, 19.4%) |
(17, 28.8%) |
(17, 14.7%) |
|
| Chronic gastritis |
(82, 46.9%) |
(28, 47.5%) |
(54, 46.6%) |
|
|
Histological AG in either antrum or body |
(N = 116) |
(n = 37) |
(n = 79) |
|
| Yes |
(67, 57.8%) |
(21, 56.8%) |
(46, 68.7%) |
0.88 |
| No |
(49, 42.2%) |
(16, 43.2%) |
(33, 41.8%) |
|
|
Histological IM in either antrum or body |
(N = 144) |
(n = 47) |
(n = 97) |
|
| Yes |
(84, 58.3%) |
(23, 48.9%) |
(61, 62.9%) |
0.11 |
| No | (60, 41.7%) | (24, 51.1%) | (36, 37.1%) |
EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d); MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.); AG, atrophic gastritis, IM, intestinal metaplasia.
All of early gastric cancer patients were cured by endoscopic submucosal dissection.
*p-value for Pearson chi-square test for comparison of categorical data, and independent samples t-test for comparison of age.